Clopidogrel: a novel antiplatelet agent.
Clopidogrel is a novel antiplatelet agent that has a different mechanism of action to aspirin. Clopidogrel is chemically related to ticlopidine, both of which are more effective than aspirin in preventing some thrombotic events, but it has a safer side-effect profile than ticlopidine. It is likely to add to the antithrombotic armoury and reduce vascular mortality and morbidity more than current therapies.
Department of Haematology, University College Hospital, London.
S
S
D'Sa
S J
SJ
Machin
D000244:Adenosine Diphosphate / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D006801:Humans; D007511:Ischemia / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014652:Vascular Diseases / Q000188:drug therapy
D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin